A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates

Biomedical Chromatography

Volumn 29, Issue 3, 2015, Pages 437-444

  Liu, Li Ya ^a,b   Han, Yong Long ^a   Zhu, Jin Hui ^a   Yu, Qi ^a   Yang, Quan Jun ^a   Lu, Jin ^a   Guo, Cheng ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cocktail; Cytochrome P450; Drug drug interaction; Inhibition; Liquid chromatography mass spectrometry

Indexed keywords

BIOMOLECULES; DRUG INTERACTIONS; ENZYME INHIBITION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROBES; SUBSTRATES; THROUGHPUT;

COCKTAIL; CYTOCHROMES P450; DRUG-DRUG INTERACTIONS; HIGH-THROUGHPUT; HUMAN LIVER MICROSOMES; IN-VITRO; INHIBITION; INHIBITION ASSAYS; LC-MS-MS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES;

METABOLITES;

AMODIAQUINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTRORPHAN; DICLOFENAC; MEPHENYTOIN; MIDAZOLAM; PARACETAMOL; RADAFAXINE; VERAPAMIL; AMFEBUTAMONE; CYTOCHROME P450 INHIBITOR; PHENACETIN;

ANALYTIC METHOD; ARTICLE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; VALIDATION PROCESS; CALIBRATION; DRUG EFFECTS; DRUG INTERACTION; HIGH THROUGHPUT SCREENING; LIMIT OF DETECTION; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

BUPROPION; CALIBRATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; LIMIT OF DETECTION; MEPHENYTOIN; MICROSOMES, LIVER; MIDAZOLAM; PHENACETIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84920941897     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3294     Document Type: Article

References (22)

1. Bapiro TE, Egnell AC, Hasler JA and Masimirembwa CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metabolism and Disposition 2001; 29: 30-35.
2. De Bock L, Vande Casteele SR, Mulliez SM, Boussery K and Van Bocxlaer JF. In vitro cytochrome P450 activity: development and validation of a sensitive high performance liquid chromatography-tandem mass spectrometry method for the quantification of six probe metabolites after derivatization with pyridine-3-sulfonyl chloride in an aqueous environment. Journal of Chromatography A 2011; 1218: 793-801.
3. De Bock L, Boussery K, Colin P, De Smet J, T'jollyn H and Van Bocxlaer J. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta 2012; 89: 209-216.
4. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H and Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition 2001; 29: 23-29.
5. Dixit V, Hariparsad N, Desai P and Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharmacy and Drug Disposition 2007; 28: 257-262.
6. Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, Weiss TS, Schwab M and Zanger UM. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metabolism and Disposition 2010; 38:1589-1597.
7. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE and Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem. Journal of the American Medical Association 2009; 281: 1728-1734.
8. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH and Shin JG. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2005; 19: 2651-2658.
9. Kozakai K, Yamada Y, Oshikata M, Kawase T, Suzuki E, Haramaki Y and Taniguchi H. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metabolism and Pharmacokinetics 2012; 27: 520-529.
10. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM and Bor DH. Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 2002; 287: 2215-2220.
11. Otten JN, Hingorani GP, Hartley DP, Kragerud SD and Franklin RB. An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metabolism Letters 2011; 5: 17-24.
12. Pillai VC, Strom SC, Caritis SN and Venkataramanan R. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2013; 74: 126-132.
13. Qin CZ, Ren X, Tan ZR, Chen Y, Yin JY, Yu J, Qu J, Zhou HH and Liu ZQ. A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Biomedical Chromatography 2014; 28: 197-203.
14. Sevior DK, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O and Ahokas JT. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010; 40: 245-254.
15. Testino SA Jr and Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2003; 30: 1459-1467.
16. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H and Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metabolism and Disposition 2004; 32: 626-631.
17. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine: Rockville, MD, 2001.
18. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Rockville, MD, 2006.
19. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2012.
20. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 2004; 32: 647-660.
21. Yin H, Racha J, Li SY, Olejnik N, Satoh H and Moore D. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 2000; 30: 141-154.
22. Zanger UM and Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacological Therapy 2013; 138: 103-141.